🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

For your dedication for patient care, clinical research, education, and for your global influence as an APAC lung cancer leader, I support you, my friend! Hidehito HORINOUCHI IASLC

#AACR25 is always a great place to share our passion for #CancerResearch, catch up on the latest breakthroughs, and spark new ideas. I had a great time connecting with fellow researchers and friends in the field. David S. Hong MD Eric K. Singhi, MD MD Anderson Cancer Center Daniel Tan

#AACR25, Dr. Simon Heek presented "Association of baseline ctDNA #EGFR mutation detection with clinical outcome in the phase II RAMOSE trial assessing ramucirumab plus osimertinibversus osimertinibin EGFR+ #LungCancer. MD Anderson Cancer Center Eric K. Singhi, MD 👉Baseline assessment of #EGFR

NVL-330 represents the next generation of HER2 TKI. High CNS penetration, high potency, sparing EGFR wt.

BN-39643 represents the newest concept of EGFR TKI, higher potency than osimertinib, CNS penetration, covering classical, C797S, PACC, and ex20 mutations, so it prevents all EGFR dependent resistance.

BAY88 has its name now, sevabertinib 😀. We are actively enrolling globally for HER2-activating mutation treatment-naive NSCLC patients.

#ASCO25 with friends and colleagues from academia and industry, from all parts of the globe, during #lungcancer poster session. Hidehito HORINOUCHI Geoff Oxnard MD Lauren Averett Byers, MD MD Anderson Cancer Center Drs. TimYap, MartinReck, MolliLi AlexSpira.

❤️ ✈️ Feeling hopeful and joyful as I leave Chicago after a productive but exhausting #ASCO25 . 💐 🎊 On the final evening, we celebrated the 10-year anniversary of #osimertinib approval—an incredible milestone—surrounded by friends and colleagues from around the world. I'm

💐💐💐Congratulations, Dr. Kelsey Pan, MD, MPH, on your graduation from the #Hematology/#Oncology Fellowship at MDACC MD Anderson Cancer Center It’s been a pleasure working with you, and I’m truly excited to now call you a fellow thoracic oncologist. I look forward to collaborating with you on

It is such a treat to discuss science with thoracic colleagues in the beautiful island of Kona, Hawaii. Eric K. Singhi, MD Jennifer A. Marks, MD OncoViews OncoDaily MD Anderson Cancer Center

We have three TKIs: firmonertinib, sunvozertinib, and zipalertinib, with FDA breakthrough designation (BTD) for EGFR Ex20ins NSCLC patients. We will change the SoC landscape soon for this patient population! EGFR Resisters Exon 20 Group, a multistakeholder organization Eric K. Singhi, MD I cannot wait to debate among

Very important study planned by Dr. Xiuning Le MD PhD :A phase I/lb study of concurrent intrathecal and intravenous amivantamab for lung cancer patients with leptomeningeal disease #DAVALung #HawaiiLung25 #lcsm #lcam MD Anderson Cancer Center

I am extremely thankful for the entire RAMOSE trial team, co-investigators, Hoosier Cancer HCRN , clinical research staff, and pts/families to complete this large multi-center randomized investigator-initiated trial (IIT) in #EGFR #lungcancer. We will report OS and other

Thank you DAVA Oncology vinay jain for another successful Lung Summit meeting! Nice to hangout and exchange scientific ideas in the beautiful island Kona with Drs. Jay Zhang, Haniel Araujo, Ferdinandos Skoulidis, John Heymach, Jia Wu, Eric K. Singhi, MD MD Anderson Cancer Center. Amazing nature.

📖 New Online: "#AI in #LungCancer Clinical Translation" — a collaborative effort between my group Dr. Erjia (EJ) Zhu erjia zhu and Dr. Jia Wu. We share insights through the lens of thoracic oncologists navigating this evolving landscape. 🔗 lnkd.in/gx6Kr_7E 👉